Abstract 264: Development of companion tests based on continuous markers: Illustration with blood-based tumor mutational burden in NSCLC cancer patients treated with atezolizumab
2021
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI